The presence in the ranking shows the company's solidity in the pharmaceutical Market. Photo: Jéssica Dona.
Prati-Donaduzzi Pharmaceutical Industry, which is based in Paraná, is about to complete 27 years of experience in the pharmaceutical market. In strong growth, the industry adds to its history important recognitions. One of them is to be part of the select list of the 1000 largest companies in Brazil, according to Valor Econômico newspaper.
The ranking was recently released and in its 20th edition brings the list of the 1000 largest companies in Brazil. Prati-Donaduzzi remains present in this important national award once again, with an increase of 35 positions compared to last year. In the pharmaceutical and cosmetic segment, it was highlighted in economic indicators such as EBITDA margin, asset turnover and profitability.
The survey methodology of Valor Econômico has the partnership of Serasa Experian and the Center for Studies in Finance of EAESP/FGV-SP. Among the items considered for the classification of companies, net revenue is one of the main parameters. Unlike previous years, due to the pandemic, the results of this edition were known in an online event.
Being one of the largest companies in Brazil is a commitment of Prati-Donaduzzi, as explained by the CEO, Eder Fernando Maffissoni. “More than rankings and numbers, our focus is on daily care for people. Every day, millions of Brazilians consume the medicines we produce, that is, we have a huge impact on the lives of the population”.
The classification in the ranking shows the strength of Prati-Donaduzzi in the pharmaceutical market. The company recently announced an investment of R$ 650 million to modernize and expand its industrial park in the coming years. “We are building a new facility that, added to the modernization of the current ones, will increase our production capacity by 40%. In full operation, we will place 17 billion doses on the market annually”, adds Maffissoni in view of further plans for the industry that is currently the largest producer of generic drugs in the country*.
Prati-Donaduzzi has a business group that grows above the market, with an expected increase of 15% per year in sales. The company moves forward with investments in the Research, Development and Innovation (RD&I) area, focused on incremental innovation and the development of new products to seek solutions mainly for diseases of the Central Nervous System, which is the focus of its new operating strategy, Medical Prescription.
Within this planning, in 2020, Prati-Donaduzzi innovated with the launch of the first product based on Cannabis, Canabidol Prati-Donaduzzi. Dozens of new products are planned for the coming years. Currently, the company sells 133 products and 409 strengths. The portfolio includes generic, branded and herbal medicines, in addition to nutraceutical products.
PRATI IN BRAZIL
Prati-Donaduzzi's medicines are found throughout the national territory. They are in more than 55 thousand pharmacies and 36 thousand basic health units. This means the opportunity for treatment for diabetics, hypertensive patients, among many other Brazilians who need them to maintain their health. It is the company's mission to consolidate itself with each dose of medicine that is consumed.
Prati-Donaduzzi, a Brazilian pharmaceutical industry, is specialized and a benchmark in the development and production of generic drugs. Headquartered in Toledo, Western Paraná, it produces approximately 12 billion therapeutic doses per year and generates more than 4,500 employments. The industry has one of the largest generic drug portfolios in Brazil and it has been working in the area of Medical Prescriptions since 2019.